達安基因(002030.SZ):猴痘病毒核酸檢測試劑盒(熒光PCR法)獲得CE註冊證書
格隆匯5月24日丨達安基因(002030.SZ)公佈,公司於中國北京時間2022年5月23日晚間獲得CE註冊證書,具體為:
產品中文名稱:猴痘病毒核酸檢測試劑盒(熒光PCR法)
英文名稱:Detection Kit for Monkeypox Virus DNA (PCR-Fluorescence Probing)
證書編號:CIBG-20224074,按照IVDD下的others類產品上市銷售。
上述產品CE註冊證書的取得豐富了公司的產品組合,拓寬了公司產品的應用領域,及時響應了海外市場的需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.